Crescent Biopharma, Inc. reported $75K of revenue over the trailing twelve months. 8 reported series are charted on this page, each one as filed. Revenue, trailing twelve months: $75K (to Q4 2022). Net income: −$96M, trailing twelve months to Q2 2026. Free cash flow: −$74M, trailing twelve months to Q2 2026.

CBIOCrescent Biopharma, Inc.

Healthcare

$14.10+25% 1Y

$14.10

$8.9452 weeks$26.98

CBIO as reported

Crescent Biopharma, Inc. reported $75K of revenue over the trailing twelve months. 8 reported series are charted on this page, each one as filed.

$75K

Revenue, trailing twelve months · to Q4 2022 · every figure below is as filed, with no scoring applied

Net income: −$96M
Net income · trailing twelve months to Q2 2026
Free cash flow: −$74M
Free cash flow · +88% year on year · trailing twelve months to Q2 2026

Details›

Every series Ryufin has for CBIO, trailing twelve months
Series	Latest	Year on year	As of
Revenue	$75K	n/a	Q4 2022 · 14 quarters behind
Net income	−$96M	n/a	Q2 2026
EPS	−$0.46	n/a	Q4 2024 · 6 quarters behind
Operating margin	−2543735%	n/a	Q3 2021 · 19 quarters behind
Net margin	−2542813%	n/a	Q3 2021 · 19 quarters behind
ROE	−50%	n/a	Q3 2021 · 19 quarters behind
ROA	−45%	n/a	Q3 2021 · 19 quarters behind
Free cash flow	−$74M	+88%	Q2 2026

Every figure straight from the statements filed with the SEC, no scoring. Per-share figures and share counts are restated for stock splits, so a split never shows up as a collapse. Open a series for its full history.